PBA
CGEM icon

Paradigm Biocapital Advisors’s Cullinan Oncology CGEM Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,321,013
Closed -$38.9M – 32
2024
Q3 		$38.9M Buy
2,321,013
+778,208
+50% +$13.8M 1.31% 25
2024
Q2 		$26.9M Buy
1,542,805
+194,790
+14% +$4.15M 1.03% 26
2024
Q1 		$23M Buy
+1,348,015
New +$20.8M 0.81% 26

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Paradigm Biocapital Advisors's CGEM Position: Q4 2024 in Review

Paradigm Biocapital Advisors sold out of Cullinan Oncology (CGEM) in Q4 2024, closing a stake of 2,321,013 shares — an estimated $38.9M sold.

Paradigm Biocapital Advisors first reported a position in CGEM in Q1 2024 and held it in 3 quarters. The position peaked at $38.9M in Q3 2024. 146 funds tracked by Wall St. Rank hold CGEM as of Q4 2024.

  • Paradigm Biocapital Advisors reported no remaining Cullinan Oncology position as of Q4 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,321,013 Cullinan Oncology shares in Q4 2024, an estimated $38.9M.
  • Paradigm Biocapital Advisors first reported a position in Cullinan Oncology in Q1 2024 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Cullinan Oncology position peaked at $38.9M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.